Sugi Predict

Sugi Predict / Compounds / SCHEMBL3460286

SCHEMBL3460286

SCHEMBL3460286

O=S(=O)(O)c1cccc(-c2ccc(F)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB1 P05556 1/20 0.50
▸ ITGA2 P17301 1/20 0.50
▸ KAT6A Q92794 1/20 0.50
▸ PTPN1 P18031 2/20 0.49
▸ TSHR P16473 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ CA2 P00918 3/20 0.44
▸ CA12 O43570 2/20 0.44
▸ CA9 Q16790 2/20 0.44
▸ ESR2 Q92731 1/20 0.44
▸ PFKFB3 Q16875 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HTR1A P08908 1/20 0.41
▸ HTR7 P34969 1/20 0.41
▸ MMP1 P03956 2/20 0.41
▸ MMP2 P08253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27903792 0.88 TSHR (0.59) KAT6APTPN1TSHRALDH1A1HSD17B10
SCHEMBL2952541 0.87 PTPN1 (0.54) KAT6APTPN1TSHRALDH1A1HSD17B10
SCHEMBL10655412 0.86 TSHR (0.54) PTPN1TSHRALDH1A1HSD17B10TDP1
SCHEMBL975190 0.86 TSHR (0.61) PTPN1TSHRALDH1A1HSD17B10TDP1
SCHEMBL307044 0.84 TSHR (0.62) KAT6APTPN1TSHRALDH1A1HSD17B10
SCHEMBL5081851 0.84 TSHR (0.59) PTPN1TSHRALDH1A1HSD17B10TDP1
SCHEMBL1416443 0.84 TSHR (0.59) PTPN1TSHRALDH1A1HSD17B10TDP1
SCHEMBL15509798 0.84 TSHR (0.59) PTPN1TSHRALDH1A1HSD17B10TDP1
Water SCHEMBL15608810 0.82 TSHR (0.60) KAT6APTPN1TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL27905022 0.82 TSHR (0.60) KAT6APTPN1TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2009-11-19 — — US claimed
EP-1931706-A4 COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS BIOTIE THERAPIES CORP (FI) 2009-05-27 — — EP claimed
US-20090023735-A1 Sulphonamide Derivatives BIOTIE THERAPIES CORP. (FI) 2009-01-22 — — US claimed
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 — — US claimed
US-20080255028-A1 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 — — US claimed
EP-1931706-A1 COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS Biotie Therapies Corp. (FI) 2008-06-18 — — EP claimed
EP-1924554-A1 SULPHONAMIDE DERIVATIVES Biotie Therapies Corp. (FI) 2008-05-28 — — EP claimed
WO-2007034035-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2007-03-29 — — WO claimed
WO-2007031608-A1 COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS BIOTIE THERAPIES CORPORATION (FI) 2007-03-22 — — WO claimed
EP-1732884-A1 SULPHONAMIDE DERIVATIVES Biotie Therapies Corp. (FI) 2006-12-20 — — EP claimed
WO-2005090298-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2005-09-29 — — WO claimed
CN-113501772-A Synthetic method of biphenyl-3-sulfonyl chloride derivative 上海毕得医药科技股份有限公司 2021-10-15 — — CN disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 — — US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 — — WO disclosed
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2009-11-19 — — US disclosed
EP-1924554-A1 SULPHONAMIDE DERIVATIVES Biotie Therapies Corp. (FI) 2008-05-28 — — EP disclosed
WO-2007034035-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2007-03-29 — — WO disclosed
WO-2007031608-A1 COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS BIOTIE THERAPIES CORPORATION (FI) 2007-03-22 — — WO disclosed
EP-1732884-A1 SULPHONAMIDE DERIVATIVES Biotie Therapies Corp. (FI) 2006-12-20 — — EP disclosed
WO-2005090298-A1 SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2005-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread NR1I2, ITGA2, ITGB2 ITGB1 9/4885ITGA2 2/4885KAT6A 2710/4885
US-20090023735-A1 Sulphonamide Derivatives HCAR1, ADGRE5, ALK ITGB1 19/4885ITGA2 15/4885KAT6A 1293/4885
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B ITGB1 2/4885ITGA2 5/4885KAT6A 3645/4885
US-20080255028-A1 Collagen Receptor I-Domain Binding Modulators COL14A1, COL2A1, COL1A1 ITGB1 8/4885ITGA2 5/4885KAT6A 3220/4885
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators COL14A1, COL2A1, COL1A1 ITGB1 8/4885ITGA2 5/4885KAT6A 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.